MANGOCEUTICALS, INC. (MGRX) IPO - S-1 Filing, Stock & Insider Activity
MANGOCEUTICALS, INC. IPO - Status & S-1 Filing
- Ticker: MGRX
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2026-01-13
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- SEC CIK: 0001938046 · View the S-1 on SEC EDGAR →
MANGOCEUTICALS, INC. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
MANGOCEUTICALS, INC. (MGRX) - no SEC Form 4 insider filings recorded in the last 90 days. 2 Form 8-K material event filings were reported by MGRX in the last 90 days. InsiderAlpha tracks every MGRX SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. trades under the ticker MGRX. InsiderAlpha tracks 11 primary SEC Form 4 filings from 5 reporting insiders for MGRX since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Services-Misc Health & Allied Services, NEC (SIC 8090) |
| SEC CIK | 0001938046 |
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 2 |
|---|---|
| Latest Form 4 filing | 2026-03-20 |
Recent MGRX Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Eugene M. Johnston | CFO | S - Open-market sale | 3.3K | $1.17 | $4K | SEC | |
| Eugene M. Johnston | CFO | S - Open-market sale | 5.0K | $1.20 | $6K | SEC | |
| Eugene M. Johnston | CFO | S - Open-market sale | 10.0K | $1.13 | $11K | SEC | |
| Alex P. Hamilton | Director | S - Open-market sale | 125.0K | $1.22 | $153K | SEC | |
| Jacob D. Cohen | Chief Executive Officer | A - Grant or award | 500.0K | $0.00 | - | SEC | |
| Kenny Myers | Director | A - Grant or award | 100.0K | $0.00 | - | SEC | |
| Lorraine Pamela D'Alessio | Director | A - Grant or award | 100.0K | $0.00 | - | SEC | |
| Alex P. Hamilton | Director | A - Grant or award | 100.0K | $0.00 | - | SEC | |
| Eugene M. Johnston | Chief Financial Officer | A - Grant or award | 100.0K | $0.00 | - | SEC | |
| Jacob D. Cohen | Chief Executive Officer | G - Bona-fide gift | 200.0K | $0.00 | - | SEC | |
| Jacob D. Cohen | Chief Executive Officer | G - Bona-fide gift | 200.0K | $0.00 | - | SEC | |
| Jacob D. Cohen | Chief Executive Officer | A - Grant or award | 200.0K | $0.00 | - | SEC | |
| Eugene M. Johnston | Chief Financial Officer | A - Grant or award | 25.0K | $0.00 | - | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for MANGOCEUTICALS, INC. (MGRX). Updated in real time as new filings are submitted to the SEC.
Recent MGRX Form 8-K Material Events
- - Item 1.01, 5.02, 5.03, 7.01, 9.01 [SEC]
- - Item 1.01, 3.02, 9.01 [SEC]
- - Item 5.02, 7.01, 9.01 · Leadership · negative [SEC]
Mangoceuticals' Board approved a repricing of CEO and Chairman Jacob Cohen's outstanding stock options on March 16, 2026, reducing the exercise price of 2,133,333 total options to $0.45 per share (the closing price that day). This repricing indicates significant stock price deter - - Item 7.01, 9.01 · Clinical · positive [SEC]
Mangoceuticals announced positive real-world data from field trials of its antiviral compound MGX-0024, including zero respiratory-related mortality in approximately 29,000-bird commercial poultry trials in India and prophylactic benefits against H5N1 in a government-conducted ch - - Item 7.01, 9.01 · Clinical · positive [SEC]
Mangoceuticals announced initial sales results from the commercial launch of its all-inclusive injectable testosterone replacement therapy (TRT) treatment program on February 19, 2026. This is a routine product launch update for an already-approved therapeutic area with no clinic
Recent Insider Filings
- - Jacob D. Cohen (Chief Executive Officer)
- - Eugene M. Johnston (CFO)
- - Eugene M. Johnston (CFO)
- - Eugene M. Johnston (CFO)
- - Alex P. Hamilton (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MGRX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
MGRX Insider Trading - FAQ
- What is the latest insider trade for MGRX?
- MANGOCEUTICALS, INC. (MGRX) had 0 insider filings in the last 90 days, with the most recent on 2026-03-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying MGRX stock?
- 0 insider purchases of MGRX were filed in the last 90 days.
- How many insiders are selling MGRX stock?
- 0 insider sales of MGRX were filed in the last 90 days.
- Where can I see MGRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks MGRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $MLYS Mineralys Therapeutics, Inc.
- $MODD Modular Medical, Inc.
- $MRUS Merus N.V.
- $MTVA MetaVia Inc.
- $NAMS NewAmsterdam Pharma Co N.V.
- $NUWE Nuwellis, Inc.
- $OBIO Orchestra BioMed Holdings, Inc.
- $ONCO Onconetix, Inc.
- $OPGN CapForce Inc.
- $OSCR Oscar Health, Inc.
Related Companies - Recent Insider Activity
- Progyny, Inc. (PGNY)
- DAVITA INC. (DVA)
- Sotera Health Co (SHC)
- agilon health, inc. (AGL)
- Marpai, Inc. (MRAI)
- VIEMED HEALTHCARE, INC. (VMD)
- CRYO CELL INTERNATIONAL INC (CCEL)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live MGRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.